Compare Baker Hughes Co (BKR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs GeneDx Holdings Corp — how do they compare? Baker Hughes Co trades at $64.54 (market cap $64.34B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Baker Hughes Co is far larger — about 26.4× GeneDx Holdings Corp's market cap, and Baker Hughes Co pays a 1.42% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BKR | WGS | |
|---|---|---|
Market Cap | $64.34B | $2.44B |
Sector | Energy | Technology |
52-Week High | $69.67 | $167.51 |
52-Week Low | $42.51 | $34.51 |
Enterprise Value | $64.86B | $2.48B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.69, up 0.97% today, with strong technical and fundamental momentum. The stock shows bullish moving averages and has beaten earnings estimates for the last three quarters. Recent news includes major contracts for subsea systems and LNG technology, supporting revenue growth. Analyst consensus is strongly positive with a $73.25 price target, indicating ~13% upside from current levels.
Outlook remains favorable driven by energy infrastructure demand and operational execution, though risks include oil price volatility and integration challenges from the Chart acquisition. The stock offers growth potential with solid cash flow and margin expansion, but investors should monitor debt levels and global energy spending trends.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
